On November 12, 2015 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that a new trial performed by the MD Anderson cancer center started, testing a combination of nivolumab, lirilumab and 5-azacytidine for the treatment of patients with Myelodysplastic Syndrome (MDS) (Press release, Innate Pharma, NOV 11, 2015, View Source [SID:1234508207]). Schedule your 30 min Free 1stOncology Demo! This is the third trial with lirilumab supported by Bristol-Myers Squibb and performed by the MD Anderson cancer center in 2015, after the opening of one trial testing the combination of lirilumab and 5-azacytidine in relapsed/ refractory AML and another trial testing the combination of lirilumab and rituximab in relapsed/ refractory or high-risk untreated CLL.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These new trials bring to 8 the number of trials performed with lirilumab, testing a broad range of solid and hematological cancer indications, multiple rationales and combinations with cytotoxic antibodies, checkpoint inhibitors and chemotherapy.